methane has been researched along with Diarrhea in 17 studies
Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed)
methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dietary fructans exacerbate symptoms in some, but not all, adults with irritable bowel syndrome (IBS)." | 9.27 | Fructans Exacerbate Symptoms in a Subset of Children With Irritable Bowel Syndrome. ( Ali, A; Chumpitazi, BP; Elsaadi, A; McMeans, AR; Orlando, S; Shulman, RJ; Vaughan, A, 2018) |
| "To investigate the association of colonic methane, formed by methanogenic achaea, and pH with gastrointestinal symptoms during colorectal cancer chemotherapy." | 9.17 | Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer. ( Blom, M; Holma, R; Korpela, R; Osterlund, P; Poussa, T; Rautio, M; Sairanen, U; Saxelin, M, 2013) |
| "We aimed to study (1) if the breath methane level on glucose breath testing (GBT) was associated with constipation severity and (2) compare methane levels between patients with constipation and diarrhea." | 7.96 | Breath Methane Does Not Correlate With Constipation Severity or Bloating in Patients With Constipation. ( Ballou, S; Duehren, S; Iturrino, J; Katon, J; Lembo, A; Nee, J; Patel, R; Rangan, V; Singh, P, 2020) |
| "Methane excretion is clearly associated with alterations in intestinal motility, particularly favouring those with constipation." | 7.78 | Reassessment of the role of methane production between irritable bowel syndrome and functional constipation. ( Bruzzone, L; Dulbecco, P; Furnari, M; Gemignani, L; Giannini, EG; Moscatelli, A; Savarino, E; Savarino, V; Zentilin, P, 2012) |
| "Methane-producing IBS patients have a unique cluster of symptoms related to constipation." | 7.77 | Factor analysis demonstrates a symptom cluster related to methane and non-methane production in irritable bowel syndrome. ( Low, K; Makhani, M; Mirocha, J; Pimentel, M; Yang, J, 2011) |
| "Dietary fructans exacerbate symptoms in some, but not all, adults with irritable bowel syndrome (IBS)." | 5.27 | Fructans Exacerbate Symptoms in a Subset of Children With Irritable Bowel Syndrome. ( Ali, A; Chumpitazi, BP; Elsaadi, A; McMeans, AR; Orlando, S; Shulman, RJ; Vaughan, A, 2018) |
| "To investigate the association of colonic methane, formed by methanogenic achaea, and pH with gastrointestinal symptoms during colorectal cancer chemotherapy." | 5.17 | Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer. ( Blom, M; Holma, R; Korpela, R; Osterlund, P; Poussa, T; Rautio, M; Sairanen, U; Saxelin, M, 2013) |
| "We aimed to study (1) if the breath methane level on glucose breath testing (GBT) was associated with constipation severity and (2) compare methane levels between patients with constipation and diarrhea." | 3.96 | Breath Methane Does Not Correlate With Constipation Severity or Bloating in Patients With Constipation. ( Ballou, S; Duehren, S; Iturrino, J; Katon, J; Lembo, A; Nee, J; Patel, R; Rangan, V; Singh, P, 2020) |
| "Lactulose breath test graphs of 561 patients of all irritable bowel syndrome subtypes were grouped into categories based on their hydrogen + methane levels with respect to time." | 3.83 | Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome. ( Adler, M; Dhingra, S; Guttermuth, C; Kasir, R; Lee, A; Zakko, P; Zakko, S, 2016) |
| "Methane excretion is clearly associated with alterations in intestinal motility, particularly favouring those with constipation." | 3.78 | Reassessment of the role of methane production between irritable bowel syndrome and functional constipation. ( Bruzzone, L; Dulbecco, P; Furnari, M; Gemignani, L; Giannini, EG; Moscatelli, A; Savarino, E; Savarino, V; Zentilin, P, 2012) |
| "Methane-producing IBS patients have a unique cluster of symptoms related to constipation." | 3.77 | Factor analysis demonstrates a symptom cluster related to methane and non-methane production in irritable bowel syndrome. ( Low, K; Makhani, M; Mirocha, J; Pimentel, M; Yang, J, 2011) |
| "We have previously shown that methane on lactulose breath test (LBT) is highly associated with constipation in IBS and that methane gas itself slows small bowel transit in dogs." | 3.72 | IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen. ( Kong, Y; Park, S; Pimentel, M, 2004) |
| "Lactose intolerance is caused by lactase enzyme deficiency in the small bowel mucosa leading to lactose malabsorption and symptoms of bloating, gas, and diarrhea." | 2.82 | Bacterial overgrowth and lactose intolerance: how to best assess. ( Ghafoor, A; Karunaratne, T; Rao, SSC, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (17.65) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Ghafoor, A | 1 |
| Karunaratne, T | 1 |
| Rao, SSC | 1 |
| Qutob, HMH | 1 |
| Saad, RA | 1 |
| Bali, H | 1 |
| Osailan, A | 1 |
| Jaber, J | 1 |
| Alzahrani, E | 1 |
| Alyami, J | 1 |
| Elsayed, H | 1 |
| Alserihi, R | 1 |
| Shaikhomar, OA | 1 |
| Divya, KM | 1 |
| Savitha, DP | 1 |
| Krishna, GA | 1 |
| Dhanya, TM | 1 |
| Mohanan, PV | 1 |
| Shah, SF | 1 |
| Jafry, AT | 1 |
| Hussain, G | 1 |
| Kazim, AH | 1 |
| Ali, M | 1 |
| Rivani, E | 1 |
| Endraswari, PD | 1 |
| Widodo, ADW | 1 |
| Khalil, MR | 1 |
| Guldberg, R | 1 |
| Nørgård, BM | 1 |
| Uldbjerg, N | 1 |
| Wehberg, S | 1 |
| Fowobaje, KR | 1 |
| Mashood, LO | 1 |
| Ekholuenetale, M | 1 |
| Ibidoja, OJ | 1 |
| Romagnoli, A | 1 |
| D'Agostino, M | 1 |
| Pavoni, E | 1 |
| Ardiccioni, C | 1 |
| Motta, S | 1 |
| Crippa, P | 1 |
| Biagetti, G | 1 |
| Notarstefano, V | 1 |
| Rexha, J | 1 |
| Perta, N | 1 |
| Barocci, S | 1 |
| Costabile, BK | 1 |
| Colasurdo, G | 1 |
| Caucci, S | 1 |
| Mencarelli, D | 1 |
| Turchetti, C | 1 |
| Farina, M | 1 |
| Pierantoni, L | 1 |
| La Teana, A | 1 |
| Al Hadi, R | 1 |
| Cicconardi, F | 1 |
| Chinappi, M | 1 |
| Trucchi, E | 1 |
| Mancia, F | 1 |
| Menzo, S | 1 |
| Morozzo Della Rocca, B | 1 |
| D'Annessa, I | 1 |
| Di Marino, D | 1 |
| Choya, A | 1 |
| de Rivas, B | 1 |
| Gutiérrez-Ortiz, JI | 1 |
| López-Fonseca, R | 1 |
| Xu, S | 1 |
| Cheng, B | 1 |
| Huang, Z | 1 |
| Liu, T | 1 |
| Li, Y | 1 |
| Jiang, L | 1 |
| Guo, W | 1 |
| Xiong, J | 1 |
| Amirazodi, M | 1 |
| Daryanoosh, F | 1 |
| Mehrabi, A | 1 |
| Gaeini, A | 1 |
| Koushkie Jahromi, M | 1 |
| Salesi, M | 1 |
| Zarifkar, AH | 1 |
| Studeny, P | 1 |
| Netukova, M | 1 |
| Nemcokova, M | 1 |
| Klimesova, YM | 1 |
| Krizova, D | 1 |
| Kang, H | 1 |
| Tao, Y | 1 |
| Zhang, Q | 1 |
| Sha, D | 1 |
| Chen, Y | 1 |
| Yao, J | 1 |
| Gao, Y | 1 |
| Liu, J | 1 |
| Ji, L | 1 |
| Shi, P | 1 |
| Shi, C | 1 |
| Wu, YL | 1 |
| Wright, AI | 1 |
| M El-Metwaly, N | 1 |
| A Katouah, H | 1 |
| El-Desouky, MG | 1 |
| El-Bindary, AA | 1 |
| El-Bindary, MA | 1 |
| Kostakis, ID | 1 |
| Raptis, DA | 1 |
| Davidson, BR | 1 |
| Iype, S | 1 |
| Nasralla, D | 1 |
| Imber, C | 1 |
| Sharma, D | 1 |
| Pissanou, T | 1 |
| Pollok, JM | 1 |
| Hughes, AM | 1 |
| Sanderson, E | 1 |
| Morris, T | 1 |
| Ayorech, Z | 1 |
| Tesli, M | 1 |
| Ask, H | 1 |
| Reichborn-Kjennerud, T | 1 |
| Andreassen, OA | 1 |
| Magnus, P | 1 |
| Helgeland, Ø | 1 |
| Johansson, S | 1 |
| Njølstad, P | 1 |
| Davey Smith, G | 1 |
| Havdahl, A | 1 |
| Howe, LD | 1 |
| Davies, NM | 1 |
| Amrillah, T | 1 |
| Prasetio, A | 1 |
| Supandi, AR | 1 |
| Sidiq, DH | 1 |
| Putra, FS | 1 |
| Nugroho, MA | 1 |
| Salsabilla, Z | 1 |
| Azmi, R | 1 |
| Grammatikopoulos, P | 1 |
| Bouloumis, T | 1 |
| Steinhauer, S | 1 |
| Mironov, VS | 2 |
| Bazhenova, TA | 2 |
| Manakin, YV | 2 |
| Yagubskii, EB | 2 |
| Yakushev, IA | 1 |
| Gilmutdinov, IF | 1 |
| Simonov, SV | 1 |
| Lan, K | 1 |
| Yang, H | 1 |
| Zheng, J | 1 |
| Hu, H | 1 |
| Zhu, T | 1 |
| Zou, X | 1 |
| Hu, B | 1 |
| Liu, H | 1 |
| Olokede, O | 1 |
| Wu, H | 1 |
| Holtzapple, M | 1 |
| Gungor, O | 1 |
| Kose, M | 1 |
| Ghaemi, R | 1 |
| Acker, M | 1 |
| Stosic, A | 1 |
| Jacobs, R | 1 |
| Selvaganapathy, PR | 1 |
| Ludwig, N | 1 |
| Yerneni, SS | 1 |
| Azambuja, JH | 1 |
| Pietrowska, M | 1 |
| Widłak, P | 1 |
| Hinck, CS | 1 |
| Głuszko, A | 1 |
| Szczepański, MJ | 1 |
| Kärmer, T | 1 |
| Kallinger, I | 1 |
| Schulz, D | 1 |
| Bauer, RJ | 1 |
| Spanier, G | 1 |
| Spoerl, S | 1 |
| Meier, JK | 1 |
| Ettl, T | 1 |
| Razzo, BM | 1 |
| Reichert, TE | 1 |
| Hinck, AP | 1 |
| Whiteside, TL | 1 |
| Wei, ZL | 1 |
| Juan, W | 1 |
| Tong, D | 1 |
| Juan, LX | 1 |
| Sa, LY | 1 |
| Jie, HFM | 1 |
| Xiao, G | 1 |
| Xiang, LG | 1 |
| Jie, HM | 1 |
| Xu, C | 1 |
| Yu, DN | 1 |
| Yao, ZX | 1 |
| Bigdeli, F | 1 |
| Gao, XM | 1 |
| Cheng, X | 1 |
| Li, JZ | 1 |
| Zhang, JW | 1 |
| Wang, W | 2 |
| Guan, ZJ | 1 |
| Bu, Y | 1 |
| Liu, KG | 1 |
| Morsali, A | 1 |
| Das, R | 1 |
| Paul, R | 1 |
| Parui, A | 1 |
| Shrotri, A | 1 |
| Atzori, C | 1 |
| Lomachenko, KA | 1 |
| Singh, AK | 1 |
| Mondal, J | 1 |
| Peter, SC | 1 |
| Florimbio, AR | 1 |
| Coughlin, LN | 1 |
| Bauermeister, JA | 1 |
| Young, SD | 1 |
| Zimmerman, MA | 1 |
| Walton, MA | 1 |
| Bonar, EE | 1 |
| Demir, D | 1 |
| Balci, AB | 1 |
| Kahraman, N | 1 |
| Sunbul, SA | 1 |
| Gucu, A | 1 |
| Seker, IB | 1 |
| Badem, S | 1 |
| Yuksel, A | 1 |
| Ozyazicioglu, AF | 1 |
| Goncu, MT | 1 |
| Zhang, H | 1 |
| Zhou, H | 1 |
| Deng, Z | 1 |
| Luo, L | 1 |
| Ong, SP | 1 |
| Wang, C | 1 |
| Xin, H | 1 |
| Whittingham, MS | 1 |
| Zhou, G | 1 |
| Maemura, R | 1 |
| Wakamatsu, M | 1 |
| Matsumoto, K | 1 |
| Sakaguchi, H | 1 |
| Yoshida, N | 1 |
| Hama, A | 1 |
| Yoshida, T | 1 |
| Miwata, S | 1 |
| Kitazawa, H | 1 |
| Narita, K | 1 |
| Kataoka, S | 1 |
| Ichikawa, D | 1 |
| Hamada, M | 1 |
| Taniguchi, R | 1 |
| Suzuki, K | 1 |
| Kawashima, N | 1 |
| Nishikawa, E | 1 |
| Narita, A | 1 |
| Okuno, Y | 1 |
| Nishio, N | 1 |
| Kato, K | 1 |
| Kojima, S | 1 |
| Morita, K | 1 |
| Muramatsu, H | 1 |
| Takahashi, Y | 1 |
| Yirgu, A | 1 |
| Mekonnen, Y | 1 |
| Eyado, A | 1 |
| Staropoli, A | 1 |
| Vinale, F | 1 |
| Zac, J | 1 |
| Zac, S | 1 |
| Pérez-Padilla, R | 1 |
| Remigio-Luna, A | 1 |
| Guzmán-Boulloud, N | 1 |
| Gochicoa-Rangel, L | 1 |
| Guzmán-Valderrábano, C | 1 |
| Thirión-Romero, I | 1 |
| Statsenko, ME | 1 |
| Turkina, SV | 1 |
| Barantsevich, ER | 1 |
| Karakulova, YV | 1 |
| Baranova, NS | 1 |
| Morzhukhina, MV | 1 |
| Wang, Q | 1 |
| Gu, Y | 1 |
| Chen, C | 1 |
| Qiao, L | 1 |
| Pan, F | 1 |
| Song, C | 1 |
| Canetto, SS | 1 |
| Entilli, L | 1 |
| Cerbo, I | 1 |
| Cipolletta, S | 1 |
| Wu, Y | 2 |
| Zhu, P | 1 |
| Jiang, Y | 1 |
| Zhang, X | 1 |
| Wang, Z | 1 |
| Xie, B | 1 |
| Song, T | 1 |
| Zhang, F | 1 |
| Luo, A | 1 |
| Li, S | 1 |
| Xiong, X | 1 |
| Han, J | 1 |
| Peng, X | 1 |
| Li, M | 1 |
| Huang, L | 1 |
| Chen, Q | 1 |
| Fang, W | 1 |
| Hou, Y | 1 |
| Zhu, Y | 1 |
| Ye, J | 1 |
| Liu, L | 1 |
| Islam, MR | 1 |
| Sanderson, P | 1 |
| Johansen, MP | 1 |
| Payne, TE | 1 |
| Naidu, R | 1 |
| Cao, J | 1 |
| Yang, J | 2 |
| Niu, X | 1 |
| Liu, X | 1 |
| Zhai, Y | 1 |
| Qiang, C | 1 |
| Niu, Y | 1 |
| Li, Z | 1 |
| Dong, N | 1 |
| Wen, B | 1 |
| Ouyang, Z | 1 |
| Zhang, Y | 1 |
| Li, J | 2 |
| Zhao, M | 1 |
| Zhao, J | 1 |
| Morici, P | 1 |
| Rizzato, C | 1 |
| Ghelardi, E | 1 |
| Rossolini, GM | 1 |
| Lupetti, A | 1 |
| Gözüküçük, R | 1 |
| Cakiroglu, B | 1 |
| He, X | 1 |
| Li, R | 1 |
| Zhao, D | 1 |
| Zhang, L | 1 |
| Ji, X | 1 |
| Fan, X | 1 |
| Chen, J | 1 |
| Wang, Y | 1 |
| Luo, Y | 1 |
| Zheng, D | 1 |
| Xie, L | 1 |
| Sun, S | 1 |
| Cai, Z | 1 |
| Liu, Q | 1 |
| Ma, K | 1 |
| Sun, X | 1 |
| Drinkwater, JJ | 1 |
| Davis, TME | 1 |
| Turner, AW | 1 |
| Davis, WA | 1 |
| Suzuki, Y | 1 |
| Mizuta, Y | 1 |
| Mikagi, A | 1 |
| Misawa-Suzuki, T | 1 |
| Tsuchido, Y | 1 |
| Sugaya, T | 1 |
| Hashimoto, T | 1 |
| Ema, K | 1 |
| Hayashita, T | 1 |
| Tansel, A | 1 |
| Levinthal, DJ | 1 |
| Chumpitazi, BP | 1 |
| McMeans, AR | 1 |
| Vaughan, A | 1 |
| Ali, A | 1 |
| Orlando, S | 1 |
| Elsaadi, A | 1 |
| Shulman, RJ | 1 |
| Singh, P | 1 |
| Duehren, S | 1 |
| Katon, J | 1 |
| Rangan, V | 1 |
| Ballou, S | 1 |
| Patel, R | 1 |
| Iturrino, J | 1 |
| Lembo, A | 1 |
| Nee, J | 1 |
| Ghoshal, UC | 2 |
| Srivastava, D | 2 |
| Ghoshal, U | 2 |
| Misra, A | 1 |
| Kasir, R | 1 |
| Zakko, S | 1 |
| Zakko, P | 1 |
| Adler, M | 1 |
| Lee, A | 1 |
| Dhingra, S | 1 |
| Guttermuth, C | 1 |
| Shukla, R | 1 |
| Makhani, M | 1 |
| Mirocha, J | 1 |
| Low, K | 1 |
| Pimentel, M | 2 |
| Furnari, M | 1 |
| Savarino, E | 1 |
| Bruzzone, L | 1 |
| Moscatelli, A | 1 |
| Gemignani, L | 1 |
| Giannini, EG | 1 |
| Zentilin, P | 1 |
| Dulbecco, P | 1 |
| Savarino, V | 1 |
| Holma, R | 1 |
| Korpela, R | 1 |
| Sairanen, U | 1 |
| Blom, M | 1 |
| Rautio, M | 1 |
| Poussa, T | 1 |
| Saxelin, M | 1 |
| Osterlund, P | 1 |
| Kong, Y | 1 |
| Park, S | 1 |
| Hallfrisch, J | 1 |
| Behall, KM | 1 |
| Ballard, CA | 1 |
| Qilligan, EJ | 1 |
| Yamagata, S | 1 |
| Ichikawa, M | 1 |
| Masamune, O | 1 |
| Mita, M | 1 |
| Takahashi, T | 1 |
| Karim, SM | 1 |
| Sharma, SD | 1 |
| Alustiza, F | 1 |
| Bellingeri, R | 1 |
| Picco, N | 1 |
| Motta, C | 1 |
| Grosso, MC | 1 |
| Barbero, CA | 1 |
| Acevedo, DF | 1 |
| Vivas, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intestinal Microbiome Fructan Metabolism and Symptom Generation in Childhood IBS[NCT02842281] | 55 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Evaluation of the Efficacy and Safety of Single, Daily Oral Doses of SYN-010 Compared to Placebo in Adult Patients With Irritable Bowel Syndrome With Constipation (EASE-DO)[NCT03763175] | Phase 2 | 59 participants (Actual) | Interventional | 2018-12-24 | Terminated (stopped due to Interim Futility Analysis) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing single-point breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing course of SYN-010
| Intervention | particles per million (Mean) |
|---|---|
| SYN-010 21 mg | -22.623 |
| SYN-010 42 mg | -4.785 |
| Placebo | -10.081 |
Subjects will record their daily bowel movements throughout the duration of the study. Change in weekly average number of CSBMs will be evaluated by comparing reported values pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Weekly average CSBMs (Least Squares Mean) |
|---|---|
| SYN-010 21 mg | 1.53 |
| SYN-010 42 mg | 0.32 |
| Placebo | 0.51 |
Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing lactulose breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | particles per million * min (Mean) |
|---|---|
| SYN-010 21 mg | -18.678 |
| SYN-010 42 mg | -20.137 |
| Placebo | -39.199 |
An overall abdominal pain intensity responder is defined as a patient with a weekly abdominal pain intensity response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response abdominal pain intensity response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 4 |
| SYN-010 42 mg | 4 |
| Placebo | 7 |
An overall bloating responder is defined as a patient with a weekly bloating response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly bloating response is defined as a weekly average bloating score of at least 30% improvement compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 3 |
| SYN-010 42 mg | 3 |
| Placebo | 1 |
An overall 12-week responder is defined as a patient with a weekly response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline and a stool frequency increase of 1 or more CSBMs per week compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 1 |
| SYN-010 42 mg | 2 |
| Placebo | 6 |
An overall stool frequency responder is defined as a patient with a weekly stool frequency response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly stool frequency response is defined as a stool frequency increase of 1 or more CSBMs per week compared with baseline, with abdominal pain unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 4 |
| SYN-010 42 mg | 6 |
| Placebo | 9 |
Subjects will record their use of rescue medication throughout the study period. Proportion of patients using rescue medication after completing the 12-week course of treatment will be compared to those reporting usage at baseline screening period. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 9 |
| SYN-010 42 mg | 11 |
| Placebo | 8 |
Outcome will be assessed by evaluating proportion of patients reporting adequate relief pre- and post-treatment on validated questionnaire. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 1 |
| SYN-010 42 mg | 2 |
| Placebo | 6 |
3 reviews available for methane and Diarrhea
| Article | Year |
|---|---|
Bacterial overgrowth and lactose intolerance: how to best assess.
Topics: Breath Tests; Diarrhea; Humans; Hydrogen; Lactase; Lactose Intolerance; Methane | 2022 |
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter | 2022 |
Understanding Our Tests: Hydrogen-Methane Breath Testing to Diagnose Small Intestinal Bacterial Overgrowth.
Topics: Breath Tests; Diarrhea; Humans; Hydrogen; Intestine, Small; Methane | 2023 |
6 trials available for methane and Diarrhea
| Article | Year |
|---|---|
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter | 2022 |
Fructans Exacerbate Symptoms in a Subset of Children With Irritable Bowel Syndrome.
Topics: Adolescent; Breath Tests; Child; Cross-Over Studies; Diarrhea; Dietary Supplements; Double-Blind Met | 2018 |
Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture.
Topics: Adolescent; Adult; Aged; Blind Loop Syndrome; Breath Tests; Diarrhea; Female; Glucose; Humans; Hydro | 2014 |
Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Breath Tests; Carcinoma; Chemotherapy, Adj | 2013 |
Breath hydrogen and methane responses of men and women to breads made with white flour or whole wheat flours of different particle sizes.
Topics: Adult; Bread; Breath Tests; Diarrhea; Digestion; Female; Flatulence; Flour; Humans; Hydrogen; Male; | 1999 |
[Influences of methylscopolammonium methylsulfate upon function of the digestive tract].
Topics: Abdomen; Adult; Clinical Trials as Topic; Diarrhea; Digestive System; Duodenal Ulcer; Electromyograp | 1972 |
9 other studies available for methane and Diarrhea
| Article | Year |
|---|---|
Breath Methane Does Not Correlate With Constipation Severity or Bloating in Patients With Constipation.
Topics: Breath Tests; Constipation; Diarrhea; Humans; Irritable Bowel Syndrome; Methane | 2020 |
Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Breath Tests; Constipation; Diarrhea; Fema | 2016 |
Irritable Bowel Syndrome, Particularly the Constipation-Predominant Form, Involves an Increase in
Topics: Adult; Aged; Area Under Curve; Breath Tests; Case-Control Studies; Constipation; Diarrhea; Feces; Fe | 2016 |
Factor analysis demonstrates a symptom cluster related to methane and non-methane production in irritable bowel syndrome.
Topics: Breath Tests; Constipation; Diarrhea; Factor Analysis, Statistical; Humans; Irritable Bowel Syndrome | 2011 |
Reassessment of the role of methane production between irritable bowel syndrome and functional constipation.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bacteria; Breath Tests; Constipation; Defec | 2012 |
IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen.
Topics: Adolescent; Adult; Aged; Breath Tests; Chromatography, High Pressure Liquid; Constipation; Diarrhea; | 2004 |
Midtrimester abortion with intramuscular injection of 15-methyl-prostaglandin E2.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Chlorpromazine; Diarrhea; Drug Evaluation; Esters; F | 1974 |
Termination of second trimester pregnancy with 15 methyl analogues of prostaglandins E 2 and F 2 .
Topics: Abortion, Therapeutic; Amnion; Diarrhea; Female; Gestational Age; Humans; Injections; Injections, In | 1972 |
IgY against enterotoxigenic Escherichia coli administered by hydrogel-carbon nanotubes composites to prevent neonatal diarrhoea in experimentally challenged piglets.
Topics: Animals; Diarrhea; Enterotoxigenic Escherichia coli; Escherichia coli Infections; Hydrogels; Immunog | 2016 |